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Process for the preparation of crystalline form III of Abemaciclib

Introduction:
The present publication relates to process for the preparation of crystalline form III of
Abemaciclib, chemically known as N-[5-[(4-ethyl-l-piperazinyl)methyl]-2-pyridinyl]-5fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine

of

Formula-1.

Formula-1
Abemaciclib is a kinase inhibitor, marketed under the tradename VERZENIO® in U.S.
by Eli Lilly USA, and is indicated for use in combination with endocrine therapy (tamoxifen
or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor
(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive,
early breast cancer at high risk of recurrence and a Ki-67 score ≥20% as determined by an
FDA approved test; in combination with an aromatase inhibitor as initial endocrine based
therapy for the treatment of postmenopausal women, and men, with hormone receptor (HR)positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic
breast cancer; in combination with Fulvestrant for treatment of women with hormone
receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative
advanced or metastatic breast cancer with disease progression following endocrine therapy.
Abemaciclib also is indicated for use as a monotherapy for the treatment of adult patients
with HR positive, HER2-negative advanced or metastatic breast cancer with disease
progression following endocrine therapy and prior chemotherapy in the metastatic setting.
U.S. Patent No. 7,855,211 discloses Abemaciclib and its pharmaceutically acceptable
salts, and discloses Abemaciclib crystalline form I, crystalline form III, amorphous
Abemaciclib, and processes for the preparation thereof.
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Brief description of the drawings:
Figure-1: Illustrates the powder X-Ray diffraction pattern of crystalline form III of
Abemaciclib of formula-1.

Detailed Description:
The schematic representation of the process for the preparation of Abemaciclib of
Formula-1 is as mentioned below:

Scheme-1

One aspect of the present publication provides a process for the preparation of
crystalline form III of Abemaciclib of Formula-1 by:
a) Suspending/dissolving Abemaciclib of formula-1 in a solvent;
b) isolating the crystalline form of Abemaciclib of formula-1.

The solvent used in step-a) is selected from alcohol solvents include but not limited to
methanol, ethanol, 1-propanol, isopropanol, 1-butanol, isobutyl alcohol, or mixtures thereof;
ketone solvents include but not limited to acetone, methyl ethyl ketone, methyl isobutyl
ketone or mixtures thereof; ester solvents include but not limited to methyl acetate, ethyl
acetate, n-propyl acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate or mixtures
thereof; chlorinated solvent include but not limited to dichloromethane, l, l-dichloroethane,
l,2-dichloroethane, chloroform, carbon tetrachloride and mixtures thereof; hydrocarbon
solvents include but not limited to toluene, hexane, heptane, or mixtures thereof; polar aprotic
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solvents include but not limited to acetonitrile, N,N-dimethylformamide (DMF), N,Ndimethylacetamide (DMA), N- methylpyrrolidone (NMP), dimethylsulfoxide (DMSO), l,2dimethoxyethane and/or mixtures thereof; suspending/ dissolving Abemaciclib of formula-1
in step-a) can be done by optionally heating the mixture to a temperature ranging from about
25°C to reflux temperature of the solvent used; isolation in step-b) is by solvent removal by
known techniques, which are selected from decanting, filtration, cooling the mixture to lower
temperatures followed by filtration of the mixture, crystallization or crystallization by adding
an anti-solvent.

In yet another aspect of the present publication, the Abemaciclib compound of
formula 1 used for the preparation of Crystalline form III of Abemaciclib of formula-1 can be
prepared by the processes known in the art and/or as described in the present application.

Abemaciclib of formula-1 prepared according to the present publication can be further
micronized or milled in conventional techniques to get the desired particle size to achieve
desired solubility profile based on different forms of pharmaceutical composition
requirements. Techniques that may be used for particle size reduction include, but not limited
to ball milling, roll milling and hammer milling, and jet milling. Milling or micronization
may be performed before drying or after the completion of drying of the product.

Additional aspect of the present publication provides a pharmaceutical composition
comprising Abemaciclib of formula-1 and one or more pharmaceutically acceptable
excipient. As used herein, the term "pharmaceutical compositions" or "pharmaceutical
formulations" include tablets, pills, powders, liquids, suspensions, emulsions, granules,
capsules, suppositories or injection preparations.

The best mode of carrying out the present publication is illustrated by the below
mentioned examples. These examples are provided as illustration only and hence should not
be considered as limitation of the scope of the publication.

Experimental Procedure:
Example-1:

Preparation

of

1-((6-bromopyridin-3-yl)methyl)-4-ethylpiperazine

of

Formula 4.
N-Ethyl piperazine of formula 5 (67.4 g) was added to the mixture of 6-Bromo
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nicotinaldehyde of formula 6 (100 g) and toluene (800 ml) at 25-35°C and stirred the reaction
mixture. The mixture was cooled to 15-25°C, sodium triacetoxy borohydride (172 g) was
added lot-wise to it and stirred at the same temperature. Quenched the reaction mixture with
water at the same temperature. Aqueous sodium hydroxide solution was added to the above
mixture at 15°-25°C and stirred. Both the layers were separated and aqueous layer was
extracted with toluene and distilled off the solvent completely from the organic layer.
Methanol (1 Lt) was added to the obtained residue at 25-30°C. Cuprous oxide (21.5 g) and
Potassium carbonate (140.9 g) were added to the above solution at 25-35°C. Applied
Ammonia gas to the reaction mixture at 25-30°C. Heated the reaction mixture to 40-45°C and
stirred. Further, heated the reaction mixture to 53-56°C under ammonia gas and stirred.
Cooled the reaction mixture to 25-30°C, filtered and washed with methanol. Distilled off the
solvent from the organic layer and co-distilled with acetone. Heated the mixture of above
obtained distillate in acetone to 55-60°C and stirred. Cooled the mixture to 45-50°C, filtered
and washed with acetone. Distilled off the solvent from the filtrate. Acetone was added to the
obtained compound. Heated the mixture to 55-60°C and stirred. Cooled the mixture to 0-5°C
and stirred at the same temperature. Filtered the solid, washed with acetone and dried to get
the title compound. Yield: 71 g.

Example-2: Preparation of 6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2methyl-1H-benzo[d]imidazole of Formula 2:
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) {herein also referred as B2pin2}
(102.7 g) added to the solution of 6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo
[d]imidazole of formula 7 (100 g) in methyl isobutyl ketone (1 L) at 25-30°C and stirred.
Potassium acetate (72.4 g) was added to the above reaction mixture at 25-30°C and purged
with nitrogen. Pd(dppf)Cl2 was added into the reaction mixture at 25-30°C, heated to 9396°C and stirred. The reaction mixture was cooled to 25-30°C, water was added, filtered
through hyflow bed and washed with methyl isobutyl ketone. Separated the layers and
aqueous layer was extracted with methyl isobutyl ketone. Combined organic layers and
washed with water. Distilled off the solvent from the organic layer and co-distilled with nheptane. To the distillate, n-heptane (400 ml) was added and stirred at 25-30°C. Filtered the
obtained solid and washed with n-heptane to get compound of formula 8. 2-butanol (1 L) was
added to the obtained compound at 25-30°C. 2,4-dichloro-5-fluoropyrimidine (61.58 g) of
formula 9 and Sodium carbonate (50.3 g) were added to the above obtained solution at 2530°C and purged with nitrogen. Tetrakis(triphenylphosphane) palladium(0) catalyst was
4
https://www.tdcommons.org/dpubs_series/5411

5

et al.: Process for the preparation of crystalline form III of Abemacicli

added into reaction mixture at the same temperature then heated to 90-95°C and stirred. The
reaction mixture was cooled to 25-30°C and water was added and stirred. The mixture was
further cooled to 2-8°C and stirred at the same temperature. Filtered the solid, washed with
chilled 2-butanol and dried to get the title compound. Yield: 72 g.

Example-3: Preparation of Abemaciclib of Formula-1.
Compound of formula 2 (71.68 g) was added to the mixture of Compound of Formula 3 (100
g), toluene (800 ml) and 2-butanol (200 ml) at 25-30°C. Potassium carbonate (85.5 g) was
added to the above mixture at 25-30°C. The reaction mixture was purged with nitrogen then
Xanthophos (2.68 g) and Tris(Dibenzylideneacetone)dipalladium (1.7 g) were added at 2530°C. Heated the reaction mixture to 95-100°C and stirred. Cooled the reaction mixture to
25-30°C, filtered through hyflow bed and washed with mixture of toluene and 2-butanol.
Water was added to the filtrate. Acidified the mixture with Hydrochloric acid and stirred at
25-30°C. Both the organic and aqueous layers were separated. Aqueous layer was washed
with toluene. Toluene was added to the obtained aqueous layer. Aqueous sodium hydroxide
solution was added to the obtained mixture, heated to 65-70°C and stirred. Both organic and
aqueous layers were separated, L-Cysteine & activated carbon were added to the organic
layer at 60-70°C. The mixture was stirred at the same temperature, filtered through hyflow
bed and washed with toluene. Distilled off the solvent from the filtrate and co-distilled with
acetonitrile. Acetonitrile was added to the distillate, heated to 75-80°C and stirred. Cooled the
mixture to 25-30°C and stirred. Filtered the solid obtained, washed with acetonitrile and dried
to get the title compound. Yield: 101 g.

Example-4: Preparation of crystalline form IV of Abemaciclib of Formula-1.
Heated the mixture of Abemaciclib of Formula 1 (75g) and methanol (750 ml) to 45-50°C
and stirred at the same temperature. Filtered the solution through hyflow bed and washed
with methanol. The obtained filtrate was cooled to 15-18°C and stirred for 10-12 hours. The
solid obtained was filtered and washed with acetonitrile. Acetonitrile (750 ml) was added to
the obtained solid at 25-30°C. Heated the mixture to 75-80°C and stirred. Cooled the mixture
to 25-30°C and stirred. Filtered the solid, washed with acetonitrile and dried to get the title
compound. Yield: 64g.

Example-5: Preparation of crystalline form III of Abemaciclib of Formula-1.
Heated the mixture of Abemaciclib (30 g) in acetonitrile (300 ml) to 80-85°C and stirred.
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Cooled the mixture to 20-25°C and stirred at the same temperature. Filtered the solid, washed
with acetonitrile and dried to get the title compound.
Yield: 25 g; PXRD of the obtained compound is depicted in Figure-1.

Example-6: Preparation of crystalline form III of Abemaciclib of Formula-1.
Dissolved Abemaciclib (50 g) in acetone (4 L) at 55-65°C and filtered for particle free
solution. Cooled the filtrate to 25-30°C and stirred. Filtered the obtained solid and dried to
get the crystalline form III of Abemaciclib.
Yield: 31.5 g; PXRD of the obtained compound is similar to the Figure-1.

Drawings

Figure-1

****
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